NASDAQ:NEPH

Nephros Stock Forecast, Price & News

$7.68

-0.32 (-4.00 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.53

Now: $7.68▼

$7.95

50-Day Range

$7.66

MA: $8.04▼

$8.58

52-Week Range

$4.42

Now: $7.68▼

$10.05

Volume22,336 shs

Average Volume14,227 shs

Market Capitalization$75.72 million

P/E RatioN/A

Dividend YieldN/A

Beta0.88

Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Overall MarketRank^™

1.16 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Nephros has a forecasted upside of 108.3% from its current price of $7.68.
Amount of Analyst Coverage
Nephros has received no research coverage in the past 90 days.

0.0 Community Rank

Outperform Votes
Nephros has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nephros has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote “Outperform” if you believe NEPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nephros does not currently pay a dividend.
Dividend Growth
Nephros does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nephros insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,870.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Nephros is held by insiders.
Percentage Held by Institutions
45.38% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Nephros are expected to grow in the coming year, from ($0.56) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nephros is -16.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nephros is -16.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nephros has a P/B Ratio of 8.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NEPH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.nephros.com

Phone201 343 5202

Employees25

Debt

Debt-to-Equity Ratio0.05

Current Ratio4.94

Quick Ratio2.68

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$10.33 million

Price / Sales7.33

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.95 per share

Price / Book8.08

Profitability

EPS (Most Recent Fiscal Year)($0.45)

Net Income$-3,420,000.00

Net Margins-43.58%

Return on Equity-36.33%

Return on Assets-26.47%

Miscellaneous

Outstanding Shares9,860,000

Market Cap$75.72 million

Next Earnings Date2/25/2021 (Estimated)

OptionableNot Optionable

$7.68

-0.32 (-4.00 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

Nephros (NASDAQ:NEPH) Frequently Asked Questions

How has Nephros' stock price been impacted by COVID-19?

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NEPH shares have increased by 2.8% and is now trading at $7.68.
View which stocks have been most impacted by COVID-19.

Is Nephros a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nephros?

Wall Street analysts have given Nephros a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nephros wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nephros' next earnings date?

Nephros is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Nephros.

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The firm earned $2.12 million during the quarter. Nephros had a negative return on equity of 36.33% and a negative net margin of 43.58%.
View Nephros' earnings history.

What guidance has Nephros issued on next quarter's earnings?

Nephros issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.31 million.

What price target have analysts set for NEPH?

1 Wall Street analysts have issued 12-month target prices for Nephros' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Nephros' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price.
View analysts' price targets for Nephros or view Wall Street analyst' top-rated stocks.

Are investors shorting Nephros?

Nephros saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 11,100 shares, an increase of 26.1% from the December 15th total of 8,800 shares. Based on an average trading volume of 15,100 shares, the short-interest ratio is currently 0.7 days.
View Nephros' Short Interest.

Who are some of Nephros' key competitors?

Some companies that are related to Nephros include iCAD (ICAD), Co-Diagnostics (CODX), IRadimed (IRMD), The Westaim (WEDXF), RenovaCare (RCAR), ClearPoint Neuro (CLPT), T2 Biosystems (TTOO), Neuronetics (STIM), Repro Med Systems (KRMD), Repro-Med Systems (REPR), TELA Bio (TELA), Soliton (SOLY), PolyPid (PYPD), Isoray (ISR) and Titan Medical (TMDI).
View all of NEPH's competitors.

Who are Nephros' key executives?

Nephros' management team includes the following people:

Mr. Andrew Astor, CEO, Pres, COO & Director (Age 63, Pay $355.61k)
Mr. Daniel S. D'Agostino, Chief Financial Officer (Age 53)
Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
Mr. Shane Sullivan, VP of Sales
Mr. Greg Lucas, Pres of Aether Water Systems

What is Nephros' stock symbol?

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $7.68.

How big of a company is Nephros?

Nephros has a market capitalization of $75.72 million and generates $10.33 million in revenue each year. The company earns $-3,420,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. Nephros employs 25 workers across the globe.

What is Nephros' official website?

The official website for Nephros is www.nephros.com.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202.

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here